Pulike Biological Engineering, Inc. (SHA:603566)
China
· Delayed Price · Currency is CNY 12.01
-0.44 (-3.53%)
Apr 29, 2026, 3:00 PM CST
SHA:603566 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 1,090 | 1,034 | 1,243 | 1,217 | 1,088 | Upgrade
|
| Other Revenue | - | 8.69 | 10.11 | 13.06 | 11.03 | Upgrade
|
| Revenue | 1,090 | 1,043 | 1,253 | 1,230 | 1,099 | Upgrade
|
| Revenue Growth (YoY) | 4.54% | -16.77% | 1.84% | 11.97% | 18.32% | Upgrade
|
| Cost of Revenue | 437.35 | 405.63 | 488.4 | 459.74 | 379.95 | Upgrade
|
| Gross Profit | 652.53 | 636.93 | 764.3 | 770.33 | 718.62 | Upgrade
|
| Selling, General & Admin | 361.59 | 413.65 | 450.03 | 473.74 | 391.87 | Upgrade
|
| Research & Development | 99.65 | 106.05 | 101.1 | 92.62 | 85.57 | Upgrade
|
| Other Operating Expenses | 1.14 | 16.6 | 14.62 | 12.77 | 11.29 | Upgrade
|
| Operating Expenses | 462.38 | 531.02 | 593.41 | 594.47 | 496.51 | Upgrade
|
| Operating Income | 190.14 | 105.91 | 170.89 | 175.86 | 222.11 | Upgrade
|
| Interest Expense | - | -0.08 | -0.92 | -0.86 | - | Upgrade
|
| Interest & Investment Income | 3.79 | 4.8 | 21.79 | 10.09 | 2.5 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 0.19 | 0.22 | 0.58 | -0.22 | Upgrade
|
| Other Non Operating Income (Expenses) | 4.81 | -0.78 | -0.73 | -0.65 | -0.56 | Upgrade
|
| EBT Excluding Unusual Items | 198.74 | 110.03 | 191.25 | 185.02 | 223.84 | Upgrade
|
| Gain (Loss) on Sale of Investments | 10.03 | -9.97 | -17.69 | -25.57 | 20.39 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.63 | -12.27 | -0.6 | -0.54 | -3.34 | Upgrade
|
| Asset Writedown | -0.8 | -1 | -0.03 | - | - | Upgrade
|
| Other Unusual Items | - | 11.98 | 21.68 | 18.81 | 43.28 | Upgrade
|
| Pretax Income | 207.34 | 98.76 | 194.61 | 177.72 | 284.18 | Upgrade
|
| Income Tax Expense | 22.34 | 5.96 | 20.1 | 9.9 | 40.04 | Upgrade
|
| Net Income | 184.99 | 92.81 | 174.52 | 167.82 | 244.14 | Upgrade
|
| Net Income to Common | 184.99 | 92.81 | 174.52 | 167.82 | 244.14 | Upgrade
|
| Net Income Growth | 99.33% | -46.82% | 3.99% | -31.26% | 7.20% | Upgrade
|
| Shares Outstanding (Basic) | 343 | 344 | 349 | 323 | 313 | Upgrade
|
| Shares Outstanding (Diluted) | 343 | 344 | 349 | 323 | 313 | Upgrade
|
| Shares Change (YoY) | -0.33% | -1.52% | 8.15% | 3.11% | -1.05% | Upgrade
|
| EPS (Basic) | 0.54 | 0.27 | 0.50 | 0.52 | 0.78 | Upgrade
|
| EPS (Diluted) | 0.54 | 0.27 | 0.50 | 0.52 | 0.78 | Upgrade
|
| EPS Growth | 100.00% | -46.00% | -3.85% | -33.33% | 8.33% | Upgrade
|
| Free Cash Flow | 281.3 | 147.73 | -22.2 | -128.8 | -105.01 | Upgrade
|
| Free Cash Flow Per Share | 0.82 | 0.43 | -0.06 | -0.40 | -0.34 | Upgrade
|
| Dividend Per Share | - | 0.400 | 0.700 | 0.350 | 0.200 | Upgrade
|
| Dividend Growth | - | -42.86% | 100.00% | 75.00% | -60.00% | Upgrade
|
| Gross Margin | 59.87% | 61.09% | 61.01% | 62.63% | 65.41% | Upgrade
|
| Operating Margin | 17.45% | 10.16% | 13.64% | 14.30% | 20.22% | Upgrade
|
| Profit Margin | 16.97% | 8.90% | 13.93% | 13.64% | 22.22% | Upgrade
|
| Free Cash Flow Margin | 25.81% | 14.17% | -1.77% | -10.47% | -9.56% | Upgrade
|
| EBITDA | 311.78 | 225.17 | 262.7 | 249.8 | 281.42 | Upgrade
|
| EBITDA Margin | 28.61% | 21.60% | 20.97% | 20.31% | 25.62% | Upgrade
|
| D&A For EBITDA | 121.63 | 119.26 | 91.81 | 73.93 | 59.31 | Upgrade
|
| EBIT | 190.14 | 105.91 | 170.89 | 175.86 | 222.11 | Upgrade
|
| EBIT Margin | 17.45% | 10.16% | 13.64% | 14.30% | 20.22% | Upgrade
|
| Effective Tax Rate | 10.78% | 6.03% | 10.33% | 5.57% | 14.09% | Upgrade
|
| Revenue as Reported | - | 1,043 | 1,253 | 1,230 | 1,099 | Upgrade
|
| Advertising Expenses | - | 10.27 | 5.54 | 7.62 | 7.54 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.